Any such publications should not be "primarily distributed by a drug or device manufacturer, but should be generally available" and should "address adequate and well-controlled clinical investigations."

— From a letter sent to the head of the FDA concerning the type of publication that can be used to promote an off-label use of a drug or device, "FDA's off-label promo guidance draws flack from Rep. Waxman," p. 4.

No Comments